Tenaya Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
TNYA Nasdaq 2836 www.tenayatherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Tenaya Therapeutics, Inc.

Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) stock price dropped 13% last week; individual investors would not be happy - Mar 24th, 2025 12:52 pm
Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models - Mar 24th, 2025 12:30 pm
Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology’s Annual Scientific Session - Mar 19th, 2025 12:30 pm
Biotech Alert: Searches spiking for these stocks today - Mar 14th, 2025 4:15 pm
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - Mar 10th, 2025 8:05 pm
Tenaya Therapeutics Announces Pricing of Public Offering - Mar 4th, 2025 4:19 am
Tenaya Therapeutics Announces Proposed Public Offering - Mar 3rd, 2025 9:10 pm
Tenaya Therapeutics to Participate in Upcoming March Investor Conferences - Mar 3rd, 2025 1:00 pm
Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine - Feb 3rd, 2025 1:30 pm
Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones - Jan 13th, 2025 2:16 pm
Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy - Dec 17th, 2024 12:00 pm
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024 - Dec 16th, 2024 9:30 pm
Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy - Nov 25th, 2024 1:30 pm
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Nov 19th, 2024 1:00 pm
Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - Nov 6th, 2024 9:05 pm
Morgan Stanley Predicts Up to 670% Jump for These 2 ‘Strong Buy’ Stocks - Nov 3rd, 2024 11:11 am
Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation - Nov 1st, 2024 1:20 pm
Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM - Oct 17th, 2024 8:30 pm
Owning 43% shares,institutional owners seem interested in Tenaya Therapeutics, Inc. (NASDAQ:TNYA), - Sep 21st, 2024 2:13 pm
Tenaya Therapeutics to Participate in Upcoming Investment Conferences - Sep 3rd, 2024 12:30 pm